GMED insider ownership: who sold, why, and what they still hold

What stands out

Three directors sold $10.7M with no disclosed plan: Stephen Zarrilli ($4.3M), David Davidar ($4.2M) and James Tobin ($2.2M). The filings don't state a reason.Stephen Zarrilli: largest such sale, Aug 18, 2026 · David Davidar: largest such sale, Nov 12, 2025 · James Tobin: largest such sale, Sep 15, 2026

A share of stake is shown for 0 of the 7 officers and directors who sold. 13 are left out

Left out: David Paul, David Davidar, Ann Rhoads, Leslie Norwalk, Dan Lemaitre, James Tobin, Kelly Huller, Stephen Zarrilli, Keith Pfeil, Robert Douglas, John DeFord, Dan Wolterman and Kyle Kline (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Stephen Zarrilli

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$4.3MNo plan disclosed

David Davidar

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$4.2MNo plan disclosed

Kelly Huller

EVP, GC, Corporate Secretary

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$3.4MDisclosed plan

James Tobin

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.2MNo plan disclosed

Kyle Kline

Senior Vice President, CFO

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.0MDisclosed plan

All 7 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 17, 2026 to Oct 16, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Sep 15, 2026James Tobin sold 30K shares ($2.2M) with no plan disclosed. 30K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
James Tobin Director	30,000	$74.58	n/a	n/a	Sep 15, 2026	Sep 16, 2026

Outside holders, reported separately

David Davidar reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Globus Medical Inc CEO selling stock?

No. Keith Pfeil reported no open-market sales in the past 12 months.

Why are Globus Medical Inc insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 39% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 61% had no disclosed plan. A trading plan schedules sales in advance.

Are any Globus Medical Inc insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold7 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Stephen Zarrilli Director	$4.3M 50K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
David Davidar Director	$4.2M 50K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Kelly Huller EVP, GC, Corporate Secretary	$3.4M 38K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
James Tobin Director	$2.2M 30K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Kyle Kline Senior Vice President, CFO	$2.0M 22K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Ann Rhoads Director	$818K 10K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Leslie Norwalk Director	$558K 6K shares	Not confirmed share of stake is being verified. Why	Disclosed plan

Sold by a charitable foundation the insider reports: Berachah Foundation, reported by David Davidar. A foundation's shares are not the insider's own stake, so they are left out of the figures above.

The full ownership picture0 of 13 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 16, 2025

Sold

Held Oct 16, 2026

Still held

David Paul

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for David Paul are complete.

Executive Chairman, Director

n/a

Vesting, gifts, unvested awards and holding lines for David Paul

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Paul are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
75,000	$53.75	Jan 26, 2034	$1.6M
75,000	$92.42	Jan 23, 2035	$0
100,000	$94.15	Jan 21, 2036	$0

Estimate: options held × ($74.58 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

David Davidar

Director

n/a

−50K

n/a

Vesting, gifts, unvested awards and holding lines for David Davidar

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Davidar are complete; balances and unit counts will be added when the check is finished.

−2.5Kgifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,000	$53.75	Jan 26, 2034	$313K
15,000	$92.42	Jan 23, 2035	$0
15,000	$94.15	Jan 21, 2036	$0

Estimate: options held × ($74.58 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Ann Rhoads

Director

n/a

−10K

n/a

Vesting, gifts, unvested awards and holding lines for Ann Rhoads

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Ann Rhoads are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,000	$53.75	Jan 26, 2034	$313K
15,000	$92.42	Jan 23, 2035	$0
15,000	$94.15	Jan 21, 2036	$0

Estimate: options held × ($74.58 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Leslie Norwalk

Director

n/a

−6K

n/a

Vesting, gifts, unvested awards and holding lines for Leslie Norwalk

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Leslie Norwalk are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,000	$53.75	Jan 26, 2034	$313K
15,000	$92.42	Jan 23, 2035	$0
15,000	$94.15	Jan 21, 2036	$0

Estimate: options held × ($74.58 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Dan Lemaitre

Director

n/a

Vesting, gifts, unvested awards and holding lines for Dan Lemaitre

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Dan Lemaitre are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
625	$65.05	Jan 14, 2031	$6K
15,000	$53.75	Jan 26, 2034	$313K
15,000	$92.42	Jan 23, 2035	$0
15,000	$94.15	Jan 21, 2036	$0

Estimate: options held × ($74.58 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

James Tobin

Director

n/a

−30K

n/a

Vesting, gifts, unvested awards and holding lines for James Tobin

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for James Tobin are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,000	$92.42	Jan 23, 2035	$0
15,000	$94.15	Jan 21, 2036	$0

Estimate: options held × ($74.58 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Kelly Huller

EVP, GC, Corporate Secretary

n/a

−38K

n/a

Vesting, gifts, unvested awards and holding lines for Kelly Huller

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kelly Huller are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
20,000	$43.58	Jan 22, 2029	$620K
40,000	$53.75	Jan 26, 2034	$833K
40,000	$92.42	Jan 23, 2035	$0
40,000	$94.15	Jan 21, 2036	$0

Estimate: options held × ($74.58 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Stephen Zarrilli

Director

n/a

−50K

n/a

Vesting, gifts, unvested awards and holding lines for Stephen Zarrilli

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Stephen Zarrilli are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,000	$53.75	Jan 26, 2034	$313K
15,000	$92.42	Jan 23, 2035	$0
15,000	$94.15	Jan 21, 2036	$0

Estimate: options held × ($74.58 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Keith Pfeil

President, CEO, Director

n/a

Vesting, gifts, unvested awards and holding lines for Keith Pfeil

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Keith Pfeil are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
833	$53.27	Jan 22, 2030	$18K
60,000	$53.75	Jan 26, 2034	$1.3M
60,000	$92.42	Jan 23, 2035	$0
40,000	$56.34	Jul 18, 2035	$730K
100,000	$94.15	Jan 21, 2036	$0

Estimate: options held × ($74.58 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Robert Douglas

Director

n/a

Vesting, gifts, unvested awards and holding lines for Robert Douglas

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Robert Douglas are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,000	$53.75	Jan 26, 2034	$313K
15,000	$92.42	Jan 23, 2035	$0
15,000	$94.15	Jan 21, 2036	$0

Estimate: options held × ($74.58 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

John DeFord

Director

n/a

Vesting, gifts, unvested awards and holding lines for John DeFord

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for John DeFord are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,000	$53.75	Jan 26, 2034	$313K
15,000	$92.42	Jan 23, 2035	$0
15,000	$94.15	Jan 21, 2036	$0

Estimate: options held × ($74.58 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Dan Wolterman

Director

n/a

Vesting, gifts, unvested awards and holding lines for Dan Wolterman

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Dan Wolterman are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,000	$53.75	Jan 26, 2034	$313K
15,000	$92.42	Jan 23, 2035	$0
15,000	$94.15	Jan 21, 2036	$0

Estimate: options held × ($74.58 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Kyle Kline

Senior Vice President, CFO

n/a

−22K

n/a

Vesting, gifts, unvested awards and holding lines for Kyle Kline

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kyle Kline are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
5,000	$80.17	Aug 9, 2031	$0
5,000	$53.14	Mar 24, 2033	$107K
10,000	$56.43	Feb 27, 2034	$182K
3,906	$51.87	Mar 14, 2034	$89K
9,091	$93.12	Jan 30, 2035	$0
20,909	$56.34	Jul 18, 2035	$381K
104	$63.68	Jan 27, 2032	$1K
30,000	$94.15	Jan 21, 2036	$0

Estimate: options held × ($74.58 − strike price), using the most recent insider trade price on Form 4 (Sep 15, 2026), not a market close.

Holdings and share of stake for Globus Medical Inc are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$17.5M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $17.5M across 205,636 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $6.8M · 39%

61%

The lighter segment is sales with no plan disclosed in the filing ($10.7M), including tax-related sales outside a plan.

No plan disclosed · $10.7M

Sales with no 10b5-1 plan and no tax reference in the filing. $4.3M of it is Stephen Zarrilli. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: James Tobin, Sep 15, 2026

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Stephen Zarrilli Director	50K	$4.3M	0%	24%	Nov 11, 2025 to Aug 18, 2026
David Davidar Director	50K	$4.2M	0%	24%	Nov 12, 2025 to Jun 5, 2026
Kelly Huller EVP, GC, Corporate Secretary	38K	$3.4M	100%	20%	Nov 25, 2025 to Feb 25, 2026
James Tobin Director	30K	$2.2M	0%	13%	Sep 15, 2026 to Sep 15, 2026
Kyle Kline Senior Vice President, CFO	22K	$2.0M	100%	12%	Dec 1, 2025 to Jan 8, 2026
Ann Rhoads Director	10K	$818K	100%	5%	Nov 7, 2025 to Nov 10, 2025
Leslie Norwalk Director	6K	$558K	100%	3%	Dec 12, 2025 to Jan 8, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$5.8M	$1.5M	$0	$4.3M
Dec 2025	$2.0M	$2.0M	$0	$0
Jan 2026	$566K	$566K	$0	$0
Feb 2026	$2.8M	$2.8M	$0	$0
Mar 2026	$0	$0	$0	$0
Apr 2026	$0	$0	$0	$0
May 2026	$0	$0	$0	$0
Jun 2026	$2.0M	$0	$0	$2.0M
Jul 2026	$0	$0	$0	$0
Aug 2026	$2.2M	$0	$0	$2.2M
Sep 2026	$2.2M	$0	$0	$2.2M
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

In line with the past 5 years. 7 insiders sold; the average is 5 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 16, 2026 Latest 12 months	206K	7	$17.5M
Oct 16, 2025 1 year earlier	284K	6	$23.5M
Oct 16, 2024 2 years earlier	200K	5	$13.5M
Oct 17, 2023 3 years earlier	80K	3	$5.3M
Oct 17, 2022 4 years earlier	57K	3	$4.2M
Oct 17, 2021 5 years earlier	703K	7	$48.9M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty13 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Globus Medical Inc are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology367 filings on record, 31 filed in the 12-month period, and how we read them

All 367 Forms 3, 4 and 5 on record for Globus Medical Inc (SEC CIK 1237831), filed from Aug 2, 2012 to Sep 16, 2026; 31 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 16, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (12)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Daniel Scavilla	Mar 28, 2025	No balance on record
David Demski	Jan 31, 2022	No balance on record
Anthony Williams	Mar 7, 2019	No balance on record
Robert Liptak	Feb 11, 2019	26,159 shares, last reported balance as of Jan 6, 2016
Kurt Wheeler	Feb 11, 2019	44,319 shares, last reported balance as of Jan 6, 2016
Steven Payne	Feb 11, 2019	No balance on record
Eric Schwartz	Jun 27, 2018	No balance on record
Brett Murphy	Feb 6, 2018	35,217 shares, last reported balance as of Nov 10, 2017
Richard Baron	May 6, 2014	No balance on record
Clarus Lifesciences I, L.P.	Sep 4, 2013	No balance on record
GOLDMAN SACHS GROUP INC	Aug 10, 2012	7,643,526 shares, last reported balance as of Aug 8, 2012
GOLDMAN SACHS PRIVATE EQUITY PARTNERS 2004 OFFSHORE HOLDINGS, L.P.	Aug 10, 2012	7,643,526 shares, last reported balance as of Aug 8, 2012

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Globus Medical Inc insiders sold $17.5M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Outside holders, reported separately

Common questions

Is the Globus Medical Inc CEO selling stock?

Why are Globus Medical Inc insiders selling?

Are any Globus Medical Inc insiders buying?

The evidence

No plan disclosed · $10.7M

Sales by month